Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of General Internal Medicine
Published in: Journal of General Internal Medicine 8/2021

01-08-2021 | Prediabetes | Capsule Commentary

Capsule Commentary on Castellon-Lopez et al.: “Psychometric Properties of the Altarum Consumer Engagement (ACE) Measure of Activation in Patients with Prediabetes”

Authors: Ana M. Palacio, MD, MPH, Elizabeth Bast, MD, MPH

Published in: Journal of General Internal Medicine | Issue 8/2021

Login to get access

Excerpt

Castellanos-Lopez et al. evaluated the psychometric properties of the Altarum Consumer Engagement (ACE) Measure™ (ACE-12), a tool to measure patient engagement1 in 3 domains: commitment, informed choice, and navigation.2 The study focuses on prediabetes, a common condition that requires patient activation for effective prevention3; patient activation can improve over time and improve self-management behaviors.4 Thus, the ACE-12 could be used to identify patients in need of activation and monitor their progress. In addition, the study validates a shorter, freely available version of the ACE tool, making it potentially useful to researchers and providers. …
Literature
1.
2.
3.
Knowler WC, Fowler SE, Hamman RF, et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet (London, England). 2009;374(9702):1677-1686.
4.
Hibbard JH, Mahoney ER, Stock R, Tusler M. Do increases in patient activation result in improved self-management behaviors? Health Serv Res. 2007 Aug;42(4):1443-63.CrossRef
5.
Bolen SD1, Chandar A, Falck-Ytter C, Tyler C, Perzynski AT, Gertz AM, Sage P, Lewis S, Cobabe M, Ye Y, Menegay M, Windish DM. Effectiveness and safety of patient activation interventions for adults with type 2 diabetes: systematic review, meta-analysis, and meta-regression. J Gen Intern Med. 2014 Aug;29(8):1166-76. https://​doi.​org/​10.​1007/​s11606-014-2855-4. Epub 2014 Apr 15.
Metadata
Title
Capsule Commentary on Castellon-Lopez et al.: “Psychometric Properties of the Altarum Consumer Engagement (ACE) Measure of Activation in Patients with Prediabetes”
Authors
Ana M. Palacio, MD, MPH
Elizabeth Bast, MD, MPH
Publication date
01-08-2021
Publisher
Springer International Publishing
Keyword
Prediabetes
Published in
Journal of General Internal Medicine / Issue 8/2021
Print ISSN: 0884-8734
Electronic ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-021-06684-x

Other articles of this Issue 8/2021

Journal of General Internal Medicine 8/2021 Go to the issue

Healing Arts

Silver Linings

Clinical Vignette

Advanced Inpatient Management of Opioid Use Disorder in a Patient Requiring Serial Surgeries

Review Paper

Tolerance for Uncertainty and Professional Development: a Normative Analysis

Innovations in Medical Education

The ACLGIM LEAD Program: a Leadership Program for Junior-Mid-Career Faculty

Letter to the Editor

Chronotherapy in COVID-19 Disease

Concise Research Report

Changes in Mortality in Top 10 Causes of Death from 2011 to 2018
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits